Dialysis Market: as CMS payment policy and hemodiafiltration platform clearances make home and high-volume dialysis modalities commercially viable at scale, the industry’s revenue base shifts from a pure in-center service model toward a hybrid product-and-service ecosystem, so incumbent providers that already own the largest in-center patient base gain a structural head start converting that base to reimbursed home therapy, and vendors that pair newly cleared hardware with unified home-management software capture the resulting platform switching costs.

The global dialysis market size was USD 105.40 Billion in 2025 and is expected to register a revenue CAGR of 5.6% during the forecast period. Market revenue growth is driven by factors such as CMS policy incentives accelerating home dialysis modality adoption, FDA clearance of next-generation high-volume hemodiafiltration platforms extending treatment options in the United States, and the continued upward trajectory of chronic kidney disease prevalence in diabetes-driven populations across Asia Pacific and Latin America. The first driving factor is CMS reimbursement policy that financially favours home dialysis modalities and rewards providers for shifting patients toward home therapy and transplant. The CMS End-Stage Renal Disease Treatment Choices Model ties provider payments to home therapy adoption and transplant rates, while the 2025 ESRD Prospective Payment System rule increased bundled payment rates for home therapies and expanded training add-ons, reducing the cost barrier for clinics and patients transitioning to home-based care. The second driving factor is FDA clearance momentum for next-generation hemodialysis platforms that bring higher-volume, higher-efficacy treatment modalities to the United States market for the first time at scale. Fresenius Medical Care received FDA 510(k) clearance in May 2025 for an updated version of its 5008X CAREsystem, a high-volume hemodiafiltration-capable platform the company estimates could replace a meaningful share of the roughly 160,000 in-center hemodialysis machines currently installed across United States dialysis centres. The third driving factor is the continued upward trajectory of chronic kidney disease and end-stage renal disease prevalence, driven substantially by rising diabetes rates in Asia Pacific and Latin America. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single integrated home dialysis platform widens its own revenue base as it unifies peritoneal dialysis and home hemodialysis management under one digital ecosystem, letting a provider capture recurring service and consumable revenue across a patient’s full home therapy journey rather than a single modality alone. Once a dialysis provider adopts an integrated home therapy management platform, extending that same platform to manage both peritoneal dialysis and home hemodialysis patients compounds the value of the initial technology investment without requiring separate systems for each modality, so the value of platform investment grows as it spans a provider’s full home therapy patient population. As a result, demand and revenue share are concentrating around providers and vendors offering unified home dialysis ecosystems, and the forecast tilts toward integrated product-and-service models rather than equipment sales alone. For instance, in June 2026, Fresenius Medical Care, Germany, launched Kinexus worldwide, a unified digital home dialysis platform architected for both peritoneal dialysis and home hemodialysis, designed to enable remote management of both modalities for healthcare organisations, clinicians, and patients under a single ecosystem. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is CMS reimbursement policy that now financially favours home dialysis modalities and rewards providers for shifting patients toward home therapy and kidney transplant. Provider revenue models respond directly to reimbursement incentives, and this dependency is what makes CMS policy the single most consequential lever shaping dialysis modality mix, so policy change and provider modality investment strategy move together closely. The CMS End-Stage Renal Disease Treatment Choices Model ties provider payments directly to home therapy adoption and transplant rates, while the 2025 ESRD Prospective Payment System rule increased bundled payment rates for home therapies and expanded training add-ons, reducing the cost hurdle for clinics and patients. The recent record shows the pace. Fresenius Medical Care and other leading providers have accelerated home therapy programme investment in direct response to these payment changes, building out the training and remote monitoring infrastructure that home modality growth requires. The effect on the market is that home dialysis modality share is growing faster than clinical demand alone would predict, reflecting the direct financial incentive CMS policy now provides. These are some of the key factors driving revenue growth of the market.

The second driver is FDA clearance of high-volume hemodiafiltration technology, a treatment modality with a stronger clinical outcomes evidence base than standard hemodialysis that has been available in other regions for years but faced a slower regulatory pathway in the United States. Hemodiafiltration commercialisation in the United States works only after FDA clearance removes the regulatory barrier that kept the modality below 1% adoption in North America compared with more than one-quarter of European hemodialysis patients, so regulatory clearance and modality conversion are directly linked in a way clinical evidence alone could not achieve. Fresenius Medical Care received FDA 510(k) clearance in May 2025 for an updated version of its 5008X CAREsystem, a high-volume hemodiafiltration-capable platform, with a broader national rollout following in 2026 across the company’s Fresenius Kidney Care clinic network. The effect on the market is that a meaningful share of the roughly 160,000 in-center hemodialysis machines currently installed in United States dialysis centres represents a multi-year replacement and upgrade opportunity as hemodiafiltration adoption accelerates. These are some of the key factors driving revenue growth of the market.

“Fresenius Medical Care estimates its FDA-cleared 5008X CAREsystem could potentially replace a meaningful share of the roughly 160,000 standard hemodialysis machines currently installed across United States dialysis centres as high-volume hemodiafiltration adoption accelerates through 2026.”

The third driver is the continued growth of the global end-stage renal disease patient population, driven substantially by rising diabetes prevalence in Asia Pacific and Latin America. Diabetes is the leading cause of chronic kidney disease progressing to end-stage renal disease, and this causal relationship means diabetes prevalence trends function as a leading indicator for future dialysis patient population growth, so the two trends move together with a multi-year lag. Countries across Asia Pacific and Latin America with rapidly rising diabetes prevalence are seeing corresponding growth in end-stage renal disease diagnosis rates, expanding the underlying dialysis patient population base that both in-center and home dialysis providers ultimately serve. The effect on the market is that underlying patient population growth provides a demand floor for dialysis market expansion independent of the reimbursement and technology-driven modality mix shifts occurring within the United States market specifically. These are some of the key factors driving revenue growth of the market.

However, the dialysis market faces severe adoption constraints from the persistent gap between home dialysis clinical potential and actual adoption rates, administrative burden imposed by prior authorization requirements, and structural barriers specific to nocturnal home hemodialysis. Because home hemodialysis and peritoneal dialysis both require substantial patient training, home infrastructure investment, and ongoing remote clinical support capability that many dialysis providers, particularly smaller and regional operators, have not fully built out, the actual share of patients on home modalities remains well below what CMS policy incentives alone would predict, reflecting a real operational capacity constraint rather than a policy design failure. Prior authorization requirements are a second constraint, because insurance approval processes for both in-center and home therapy patients create meaningful financial and operational strain for dialysis providers, with sizeable administrative staff time devoted to navigating payer requirements rather than clinical care delivery or technology adoption, and this administrative burden disproportionately affects smaller providers with less dedicated administrative capacity. Nocturnal home hemodialysis adoption barriers are the third constraint, since despite documented clinical benefits including improved outcomes and quality of life, structural barriers including patient and caregiver burden, reimbursement complexity for extended overnight treatment sessions, and limited provider training capacity have kept nocturnal home hemodialysis a niche modality relative to its clinical potential, so the most clinically beneficial home modality remains the least adopted. These factors substantially limit dialysis market growth over the forecast period.

Based on type, the global dialysis market is segmented into hemodialysis and peritoneal dialysis. Hemodialysis holds the largest revenue share, because it remains the dominant modality for the majority of the global end-stage renal disease patient population, which suits the market’s deep installed base of in-center hemodialysis infrastructure. Peritoneal dialysis remains established as the primary home modality option in many markets, and it offers lower infrastructure requirements for home use, but it has not matched hemodialysis’s overall patient volume given clinical suitability differences across patient populations. Peritoneal dialysis is expected to register the fastest revenue growth rate in the global dialysis market over the forecast period, driven by CMS home therapy reimbursement incentives and Vantive’s continued peritoneal dialysis portfolio expansion, which is why home-modality-focused providers are prioritising peritoneal dialysis programme growth.

In-center dialysis modality is expected to account for the largest revenue share in the global dialysis market during the forecast period

Based on modality, the global dialysis market is segmented into in-center dialysis, home hemodialysis, and home peritoneal dialysis. In-center dialysis holds the largest revenue share, reflecting its position as the default treatment setting for the majority of dialysis patients globally, which suits the deep installed base of freestanding dialysis clinics operated by Fresenius Medical Care and DaVita. Home hemodialysis is expected to register the fastest revenue growth rate in the global dialysis market over the forecast period, driven by CMS ETC Model incentives and FDA clearance of home-capable hemodialysis systems such as the Quanta Dialysis System, which is why home hemodialysis represents the leading edge of the industry’s modality mix shift.

Based on the product versus service split, the global dialysis market is segmented into dialysis equipment and consumables, and dialysis care services. Dialysis care services hold the largest revenue share, reflecting the recurring, high-frequency nature of dialysis treatment delivery relative to episodic equipment capital purchases, which suits the integrated care delivery model that Fresenius Medical Care and DaVita both operate. Dialysis equipment and consumables are expected to register rapid revenue growth in the global dialysis market over the forecast period, driven by hemodiafiltration platform replacement cycles and expanding home therapy device placements, which is why equipment vendors are prioritising next-generation platform development.

Based on regional analysis, the dialysis market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of freestanding dialysis clinic infrastructure globally, anchored by Fresenius Medical Care and DaVita, and because CMS reimbursement policy directly shapes global industry modality strategy given the scale of the United States dialysis patient population. Fresenius Medical Care’s May 2025 5008X CAREsystem clearance and subsequent 2026 national rollout both concentrate first in the United States dialysis clinic network. The concentration of CMS reimbursement policy and FDA clearance activity in the United States also means new dialysis technology platforms are typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national dialysis markets within Europe. Hemodiafiltration is already the established treatment standard across much of Europe, meaning the technology-driven growth catalyst reshaping the United States market has already played out regionally, and national health system dialysis infrastructure across the region is comparatively mature. The result is steady rather than rapid growth, shaped more by the region’s already-advanced treatment modality adoption than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and India represent the three largest national dialysis markets within the region. Rapidly rising diabetes-driven chronic kidney disease prevalence and expanding dialysis clinic infrastructure investment in China and India are driving demand from a comparatively lower installed treatment capacity base relative to patient population, leaving substantially more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate-to-rapid revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national dialysis markets within the region. Rising diabetes-driven end-stage renal disease prevalence is expanding the underlying patient population, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised dialysis equipment and consumables that Latin American dialysis clinics depend on through 2026, slowing infrastructure expansion beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial dialysis markets within the GCC. Saudi Arabia is the most established dialysis market on the continent given its extensive government-funded dialysis clinic network, while the wider Gulf states and broader African markets are still building dialysis treatment infrastructure to match rising chronic kidney disease prevalence.